TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12798886

Group type: COMPARATOR
Intervention: Goserelin (3.6 mg, s.c. injection)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Fulvestrant (50 mg, 125 mg, or 250 mg, i.m. injection)
Number of subjects: 307
Study: 10827391

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 29
Study: 8719647

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (25-50 U)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (intramuscular saline)
Number of subjects: 17
Study: 1711873

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids (all types)
Number of subjects: 0
Study: 6130751

Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive psychotherapy (ST)
Number of subjects: 0
Study: 3875451

Group type: EXPERIMENTAL
Intervention: 200 mg pirazolac 3-times daily for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium 3-times daily for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28940213

Group type: EXPERIMENTAL
Intervention: Habit reversal treatment (HR) + mometasone furoate (potent steroid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mometasone furoate (potent steroid) alone
Number of subjects: 39
Study: 27684483

Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL) procedure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 53
Study: 24071762

Group type: EXPERIMENTAL
Intervention: Pentaerithrityl tetranitrate (PETN) 80 mg b.i.d.
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study: 22533659

Group type: EXPERIMENTAL
Intervention: Intervention targeting physician, patient, and office system factors
Number of subjects: 591

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 591
Study: 20064822

Group type: EXPERIMENTAL
Intervention: Statins (Group 1)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: RAAS inhibitors (Group 2)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control (Group 3)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: RAAS inhibitors
Number of subjects: 372

Group type: COMPARATOR
Intervention: Statins vs Control
Number of subjects: 372

Group type: COMPARATOR
Intervention: RAAS inhibitors vs Control
Number of subjects: 372
Study: 19018483

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terlipressin in combination with albumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terlipressin and albumin
Number of subjects: 0
Study: 15671799

Group type: EXPERIMENTAL
Intervention: Didanosine and Stavudine (ddI+d4T)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Abacavir and Lamivudine (ABC+3TC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 96
Study: 12552210

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + 1 microg neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + 2.5 microg neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + 5 microg neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 microg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60
Study: 10550412

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 0
Study: 8681637

Group type: EXPERIMENTAL
Intervention: LPS (lipopolysaccharide) inhalation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CDE (corn dust extract) inhalation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-endotoxin LPS and CDE exposures
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-endotoxin LPS and CDE exposures
Number of subjects: 14
Study: 1869725

Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone
Number of subjects: 510
Study: 6857251

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control animals (dissociated drug histories)
Number of subjects: 0
Study: 29578381

Group type: EXPERIMENTAL
Intervention: Increased stride length
Number of subjects: 19

Group type: COMPARATOR
Intervention: Shorter stride length
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Longer stride length
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Longer strides
Number of subjects: 19
Study: 29463612

Group type: EXPERIMENTAL
Intervention: CTO-PCI
Number of subjects: 302

Group type: COMPARATOR
Intervention: CTO-No PCI
Number of subjects: 302
Study: 27014997

Group type: EXPERIMENTAL
Intervention: Secukinumab (IV 10 mg/kg at weeks 0, 2, 4 followed by subcutaneous 150 mg or 75 mg)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Secukinumab (IV→150 mg)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Secukinumab (IV→75 mg)
Number of subjects: 606
Study: 24613784

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LC patients
Number of subjects: 82

Group type: COMPARATOR
Intervention: Diagnosis (LC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Functional status
Number of subjects: 82
Study: 23281381

Group type: EXPERIMENTAL
Intervention: Conventional catheterization + bedside fluoroscopy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional catheterization
Number of subjects: 168
Study: 20204511

Group type: EXPERIMENTAL
Intervention: Navigator intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study: 18629732

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention consisting of education and psychological support, with or without pharmacological therapy, associated with follow-up phone calls
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 196
Study: 15870599

Group type: EXPERIMENTAL
Intervention: Randomization performed in trials
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Masking in medical treatments
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Comparison of basal characteristics
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Patient losses during follow-up
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Reporting of P values
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Measure of effect reported
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Trials performed in the US
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Presence of statistician or epidemiologist
Number of subjects: 226
Study: 11796083

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified biscuit (beta-carotene, iron, and iodine)
Number of subjects: 108
Study: 9704197

Group type: EXPERIMENTAL
Intervention: Zaltoprofen
Number of subjects: 46
Study: 8310980

Group type: EXPERIMENTAL
Intervention: Hospitalized group
Number of subjects: 311
Study: 2647846

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg once daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Withdrawal of treatment
Number of subjects: 8
Study: 1091665

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 40

Group type: COMPARATOR
Intervention: Previous medication
Number of subjects: 40
Study: 29927290

Group type: EXPERIMENTAL
Intervention: Family based reintegration program aimed at enhancing reflective functioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline relationship satisfaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Couple distress
Number of subjects: 0
Study: 28241386

Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 178
Study: 26710315

Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (placebo)
Number of subjects: 0
Study: 25081673

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Class group
Number of subjects: 60
Study: 22648444

Group type: EXPERIMENTAL
Intervention: Active low-level light therapy (LLLT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 31
Study: 19431196

Group type: EXPERIMENTAL
Intervention: Presence of promoter hypermethylation of p16 gene
Number of subjects: 38

Group type: COMPARATOR
Intervention: Histologically free margins
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Positive molecular margins
Number of subjects: 38
Study: 17692110

Group type: EXPERIMENTAL
Intervention: Lutropin alfa 75 IU and follitropin alfa (75-225 IU)
Number of subjects: 31
Study: 15039504

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12739312

Group type: EXPERIMENTAL
Intervention: Triptans (acute migraine pharmacotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public health initiatives
Number of subjects: 0
Study: 9287046

Group type: EXPERIMENTAL
Intervention: rhIGF-I (50 microg/kg b.i.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8281563

Group type: EXPERIMENTAL
Intervention: Low-fluoride solution (0.5% F) applied 10 times a year
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard topical amine fluoride solution (1% F)
Number of subjects: 199
Study: 2883491

Group type: EXPERIMENTAL
Intervention: 13C-urea breath test
Number of subjects: 26

Group type: COMPARATOR
Intervention: Endoscopic biopsy
Number of subjects: 26
Study: 30618475

Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-4.5 mg/day)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 26499921

Group type: EXPERIMENTAL
Intervention: E10030 (0.03 mg) in combination with ranibizumab (0.5 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg)
Number of subjects: 23
Study: 24860156

Group type: EXPERIMENTAL
Intervention: 80% oxygen during and for 2 h after surgery
Number of subjects: 1386

Group type: COMPARATOR
Intervention: 30% oxygen during and for 2 h after surgery
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1386

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Localized disease
Number of subjects: 1386
Study: 22900702

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (400 mg, equivalent to 2 cups of coffee)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study: 20425165

Group type: EXPERIMENTAL
Intervention: CorCap Cardiac Support Device (Acorn Cardiovascular, St. Paul, MN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery insights
Number of subjects: 0
Study: 17693101

Group type: EXPERIMENTAL
Intervention: Inserted insole without shoes
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Strapped insole with shoes
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Strapped insole without shoes
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo with shoes
Number of subjects: 207

Group type: COMPARATOR
Intervention: Inserted insole with shoes
Number of subjects: 207
Study: 17064525

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao 500 mg three times daily for 5 days
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Number of subjects: 197
Study: 14655910

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study: 10640625

Group type: EXPERIMENTAL
Intervention: CO(2) laser stimulation of the dorsum of the left hand
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electric stimulation of the left median nerve at wrist
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Direct recording of somatosensory evoked potentials (SEPs) from peri‐Rolandic cortex
Number of subjects: 12
Study: 8667142

Group type: EXPERIMENTAL
Intervention: Flap with osseous resection surgery (FO)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Modified Widman surgery (MW)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Root planing (RP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Coronal scaling (CS)
Number of subjects: 82
Study: 8213620

Group type: EXPERIMENTAL
Intervention: Compensated split-course radiotherapy (300 cGy x 10, 3 weeks rest, 300 cGy x 10)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous radiotherapy (200‐220 cGy up to 6000‐6600 cGy)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Compensated split-course radiotherapy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous radiotherapy
Number of subjects: 137
Study: 3799505

Group type: EXPERIMENTAL
Intervention: 1000 mg of elemental calcium for 8 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Calcium supplementation in mildly hyperlipidemic normotensive subjects
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 70
Study: 31514854

Group type: EXPERIMENTAL
Intervention: FT-IR spectroscopy
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: FT-NIR spectroscopy
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: ATR-MIR spectroscopy
Number of subjects: 900
Study: 29426006

Group type: EXPERIMENTAL
Intervention: Ayurvedic treatment (multi-modal)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional care (multi-modal)
Number of subjects: 151
Study: 27884120

Group type: EXPERIMENTAL
Intervention: PMMA filter (Filtryzer BK‐F)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HFR17 filter
Number of subjects: 20

Group type: COMPARATOR
Intervention: F7 filter
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All filters
Number of subjects: 20
Study: 24857271

Group type: EXPERIMENTAL
Intervention: iPad-based image guidance system
Number of subjects: 5

Group type: COMPARATOR
Intervention: 3-dimensional mouse interface
Number of subjects: 5
Study: 22834721

Group type: EXPERIMENTAL
Intervention: Usual care and support from a chosen close female relative from admission until 2 hours after birth
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 120
Study: 19196894

Group type: EXPERIMENTAL
Intervention: eMPC algorithm
Number of subjects: 120

Group type: COMPARATOR
Intervention: Matias protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bath protocol
Number of subjects: 120
Study: 17765316

Group type: EXPERIMENTAL
Intervention: p38-MAPK inhibitors
Number of subjects: 0
Study: 14999030

Group type: EXPERIMENTAL
Intervention: Home-based progressive strength, balance, and general physical activity intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Attention-control group (home-based nutrition education)
Number of subjects: 72
Study: 12052577

Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (pharmaceutical heroin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) application of heroin under medical supervision
Number of subjects: 0
Study: 9621802

Group type: EXPERIMENTAL
Intervention: Nutridrink (early enteral nutrition)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 7938560

Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 3356050

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 50 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 46
Study: 29055882

Group type: EXPERIMENTAL
Intervention: Exposure to NAS advertisements
Number of subjects: 1128

Group type: COMPARATOR
Intervention: No-message control group
Number of subjects: 1128
Study: 27146725

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 145
Study: 25898367

Group type: EXPERIMENTAL
Intervention: Traditional cognitive training
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Robot-assisted cognitive training
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 85
Study: 23639047

Group type: EXPERIMENTAL
Intervention: FeNO > 20 ppb in non-asthmatics
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: FeNO > 20 ppb in asthmatics
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: FeNO as a predictor of atopy
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: FeNO in non-asthmatics
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: FeNO in asthmatics
Number of subjects: 1119
Study: 19948873

Group type: EXPERIMENTAL
Intervention: TSC 30%
Number of subjects: 6

Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 6
Study: 18230250

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination drugs (FDCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loose drugs
Number of subjects: 0
Study: 16340598

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 12884988

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with 8% sevoflurane and nitrous oxide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway insertion with 8% sevoflurane and nitrous oxide
Number of subjects: 60
Study: 11126178

Group type: COMPARATOR
Intervention: Serum concentration of carboxyterminal propeptyde of procollagen type I (P I CP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Serum concentration of aminoterminal propeptyde of procollagen type III (P III NP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Serum concentration of carboxyterminal telopeptyde of collagen type I (I CTP)
Number of subjects: 25
Study: 8648207

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study: 1346562

Group type: EXPERIMENTAL
Intervention: Pirbuterol 0.4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirbuterol 0.8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirbuterol 1.2 mg
Number of subjects: 0
Study: 6437131

Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tocainide HCl (900 mg daily)
Number of subjects: 22
Study: 30621783

Group type: EXPERIMENTAL
Intervention: Open-CSAM
Number of subjects: 0

Group type: COMPARATOR
Intervention: SMASH, MyoVision, MuscleJ
Number of subjects: 0
Study: 30594169

Group type: EXPERIMENTAL
Intervention: Endometrial scratching in the luteal phase of the natural cycle
Number of subjects: 792

Group type: COMPARATOR
Intervention: Control group (no endometrial scratching)
Number of subjects: 792
Study: 27456602

Group type: EXPERIMENTAL
Intervention: Stair-step incision
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inverted V incision
Number of subjects: 58
Study: 24488498

Group type: EXPERIMENTAL
Intervention: Low-dose enteric-coated aspirin tablets (100 mg/day for 2 years)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 22994910

Group type: EXPERIMENTAL
Intervention: Maternal and child health nurse (MCHN) IPV screening intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Composite Abuse Scale for measuring IPV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Process and impact evaluation data (online surveys and key stakeholders interviews)
Number of subjects: 8
Study: 20179259

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 100
Study: 17688921

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: UBC-ELISA
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cytology and FISH
Number of subjects: 166

Group type: COMPARATOR
Intervention: False-positive results of FISH
Number of subjects: 166

Group type: COMPARATOR
Intervention: False-positive results of UBC
Number of subjects: 166

Group type: COMPARATOR
Intervention: False-positive results of cytology
Number of subjects: 166
Study: 15675981

Group type: EXPERIMENTAL
Intervention: rHuEPO therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no rHuEPO therapy)
Number of subjects: 30
Study: 12002961

Group type: EXPERIMENTAL
Intervention: Affirmative action plans with special training opportunities for minorities
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Affirmative action plans (various contents)
Number of subjects: 1173
Study: 10197560

Group type: EXPERIMENTAL
Intervention: Diet only (4.19-5.44 MJ/d)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Exercise only (five, 45-min sessions/wk at 78.5 +/- 0.5% of maximum heart rate)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both exercise and diet
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (no diet or exercise)
Number of subjects: 98
Study: 8869020

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (CGP 39,393/TMREVASC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 2266990

Group type: EXPERIMENTAL
Intervention: Mazindol (3 mg/d)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 6106828

Group type: EXPERIMENTAL
Intervention: sulphinpyrazone (SPZ) 200 mg orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15